0RA2 Stock Overview
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Poxel S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.75 |
| 52 Week High | €0.92 |
| 52 Week Low | €0.30 |
| Beta | 1.57 |
| 1 Month Change | 44.10% |
| 3 Month Change | 66.45% |
| 1 Year Change | 12.20% |
| 3 Year Change | -88.35% |
| 5 Year Change | -89.38% |
| Change since IPO | -90.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RA2 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 20.1% | -0.2% | 2.3% |
| 1Y | 12.2% | -29.5% | 0.6% |
Return vs Industry: 0RA2 exceeded the UK Biotechs industry which returned -29.8% over the past year.
Return vs Market: 0RA2 exceeded the UK Market which returned 0.3% over the past year.
Price Volatility
| 0RA2 volatility | |
|---|---|
| 0RA2 Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0RA2's share price has been volatile over the past 3 months.
Volatility Over Time: 0RA2's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 15 | Thomas Kuhn | www.poxelpharma.com |
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications.
Poxel S.A. Fundamentals Summary
| 0RA2 fundamental statistics | |
|---|---|
| Market cap | €29.22m |
| Earnings (TTM) | -€44.24m |
| Revenue (TTM) | €1.55m |
18.9x
P/S Ratio-0.7x
P/E RatioIs 0RA2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RA2 income statement (TTM) | |
|---|---|
| Revenue | €1.55m |
| Cost of Revenue | €1.54m |
| Gross Profit | €2.00k |
| Other Expenses | €44.24m |
| Earnings | -€44.24m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 0.13% |
| Net Profit Margin | -2,861.58% |
| Debt/Equity Ratio | -112.1% |
How did 0RA2 perform over the long term?
See historical performance and comparison